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A B S T R A C T
Background
Cholecystectomy is not required in up to 64% of patients who adopt a wait-and-see policy after endoscopic clearance of common bile
duct stones. Although reports of retrospective cohort series have shown a higher mortality among patients who defer cholecystectomy,
it is not known if this is due to the patients’ premorbid health status or due to the deferral of cholecystectomy. Randomised clinical
trials of prophylactic cholecystectomy versus wait-and-see have not had sufficient power to demonstrate differences in survival.
Objectives
To evaluate the beneficial and harmful effects of cholecystectomy deferral (wait-and-see) versus elective (prophylactic) cholecystectomy
in patients who have had an endoscopic biliary sphincterotomy.
Search strategy
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Controlled Trials Register (CENTRAL) in
The Cochrane Library, MEDLINE (1966 to 2007), EMBASE (1980 to 2007), and Science Citation Index Expanded without language
restrictions until April 2007.
Selection criteria
Randomised clinical trials comparing patients whose gallbladder was left in-situ after endoscopic sphincterotomy (wait-and-see group)
versus patients who had cholecystectomy with either endoscopic sphincterotomy or common bile duct exploration (prophylactic
cholecystectomy group), irrespective of blinding, language, or publication status.
Data collection and analysis
We assessed the impact of a wait-and-see policy onmortality. Secondary outcomes assessed were the incidence of biliary pain, cholangitis,
pancreatitis, need for cholangiography, need for cholecystectomy, and the rate of difficult cholecystectomy.We pooled data using relative
risk with fixed-effect and random-effects models.
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Main results
We included 5 randomised trials with 662 participants out of 93 publications identified through the literature searches. The number
of deaths was 47 in the wait-and-see group (334 patients) compared to 26 in the prophylactic cholecystectomy group (328 patients)
for a 78% increased risk of mortality (RR 1.78, 95% CI 1.15 to 2.75, P = 0.010). The survival benefit of prophylactic cholecystectomy
was independent of trial design, inclusion of high risk patients or inclusion of any one of the five trials. Patients in the wait-and-see
group had higher rates of recurrent biliary pain (RR 14.56, 95% CI 4.95 to 42.78, P < 00001), jaundice or cholangitis (RR 2.53,
95% CI 1.09 to 5.87, P = 0.03), and of repeat ERCP or other forms of cholangiography (RR 2.36, 95% CI 1.29 to 4.32, P = 0.005).
Cholecystectomy was eventually performed in 35% (115 patients) of the wait-and-see group.
Authors’ conclusions
Prophylactic cholecystectomy should be offered to patients whose gallbladders remain in-situ after endoscopic sphincterotomy and
common bile duct clearance.
P L A I N L A N G U A G E S U M M A R Y
Prophylactic cholecystectomy should be offered to patients whose gallbladders remain in-situ after endoscopic sphincterotomy
and common bile duct clearance
Surgical removal of the gallbladder is done routinely. Stones in the common bile duct usually come from the gallbladder and can
be harmful. The usual treatment for gallstones that are in the common bile duct is endoscopic retrograde cholangiopancreatography
(ERCP) and sphincterotomy. ERCP is an endoscopic procedure to remove stones from the common bile duct. More stones may
enter the common bile duct from the gallbladder but it is not clear if the gallbladder should be removed preventively (prophylactic
cholecystectomy) or if a wait-and-see policy (cholecystectomy deferral) would be better. We included 5 randomised trials with 662
participants out of 93 publications identified through the literature searches. The number of deaths was 47 in the wait-and-see group
(334 patients) compared with 26 in the prophylactic cholecystectomy group (328 patients). This review of randomised clinical trials
suggests that early removal of the gallbladder decreases the risk of death or of complications from gallstones. The number of patients
(662) reviewed in this report prevents some of the subgroup analyses from being conclusive. Further clinical trials, particularly of high-
risk patients, would solve this problem.
B A C K G R O U N D
Prior to the development of endoscopic retrograde cholangio-
pancreatography (ERCP) the treatment of choledocholithiasis-re-
lated illness was open cholecystectomy and common bile duct ex-
ploration if operative cholangiography confirmed the presence of
residual stones in the bile duct. ERCP permits removal of biliary
stones without open operation. The importance of its role in the
management of choledocholithiasis increased with the develop-
ment of the laparoscopic approach to cholecystectomy, which ini-
tially limited surgical access for common duct exploration (NIH
1992). Patients with suspected choledocholithiasis were advised
to undergo ERCP and endoscopic biliary sphincterotomy before
laparoscopic cholecystectomy was considered (Roy 1993; NIH
2002). The role of ductal pressure in biliary symptoms suggests
that some patients may be managed by sphincterotomy alone be-
cause it reduces pressure in the biliary tree. Deferral of cholecystec-
tomy after endoscopic sphincterotomy for choledocholithiasis in
high-risk patients was first reported almost twenty-five years ago
(Escourrou 1984). Only 13% of 224 patients followed for three
years required cholecystectomy. Currently, deferral of cholecystec-
tomy (also known as wait-and-see) is advised in high-risk patients
whose choledocholithiasis has been cleared by ERCP (NIH1992).
In contrast, retrospective reviews found a higher mortality rate in
patients who deferred cholecystectomy after endoscopic sphinc-
terotomy compared to patients who had their gallbladders re-
moved electively (Archibald2007).Only randomised clinical trials
could have determined if prophylactic cholecystectomy reduced
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the risk of death. A recent randomised clinical trial of prophy-
lactic cholecystectomy versus wait-and-see in fit patients found a
higher incidence of biliary symptoms in the wait-and-see group,
of whom 22 (36%) had cholecystectomy performed in the first
20 months after sphincterotomy (Boerma 2002). No differences
were seen in patient survival or in quality of life, but the trial was
underpowered for such determinations. An accompanying edito-
rial advised fit patients to undergo prophylactic cholecystectomy
following clearance of stones from the bile duct (Cuschieri 2002).
This editorial also suggested that the technique for laparoscopic
common bile duct exploration had advanced and that it was now
the preferred method over ERCP to clear ductal stones because
prophylactic cholecystectomy could be performed at the same op-
eration. However, this view is not universally accepted (Barkun
2005).
A systematic review of randomised clinical trials is required to
determine the benefits and harms of cholecystectomy deferral after
endoscopic sphincterotomy versus prophylactic cholecystectomy
after either ERCP or common bile duct exploration.
O B J E C T I V E S
To evaluate the beneficial and harmful effects of cholecystectomy
deferral (wait-and-see) versus elective (prophylactic) cholecystec-
tomy in patients who have had an endoscopic biliary sphinctero-
tomy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials were included irrespective of blinding, lan-
guage, or publication status (ie, unpublished trials, abstracts, or
full paper articles).
Types of participants
Patients with gallbladders left in-situ after endoscopic sphinctero-
tomy.
Types of interventions
Expectantmanagement (cholecystectomy deferral) versus prophy-
lactic (elective) cholecystectomy. Randomised clinical trials that
compared endoscopic sphincterotomy followedby expectantman-
agement of the gallbladder with either endoscopic sphincterotomy
followed by prophylactic cholecystectomy or with common bile
duct exploration and prophylactic cholecystectomywere included.
Collateral interventions were permitted if applied equally in both
arms of the trial.




(2) Incidence of: biliary pain; recurrent jaundice; pancreatitis;
non-biliary abdominal pain; major adverse events; minor adverse
events; other morbidities.
(3) Number of patients undergoing subsequent ERCP or percu-
taneous cholangiogram.
(4) Number of patients undergoing cholecystectomy.
(5) Incidence of ’complicated’ cholecystectomy (complicated is
defined as the unintended extension of surgery such as conversion
of laparoscopic to open cholecystectomy or use of cholecystostomy
prior to cholecystectomy).
(6) Quality of life.
(7) Number of patients requiring re-admission to hospital.
(8) Adverse events. They were classified as major if they were con-
sidered to threaten life, organ or limb function or to substantially
prolong hospital stay. Examples of major adverse events include
bile duct transection, myocardial infarction, pulmonary embolism
and renal failure. Other adverse events were considered to be mi-
nor adverse events. Examples of minor adverse events include cys-
tic duct bile leak, respiratory atelectasis and wound infections (
ICH-GCP 1997).
Search methods for identification of studies
We performed electronic searches using the search strategies pre-
sented in Appendix 1. We manually went through the results ob-
tained through the searches in The Cochrane Hepato-Biliary Group
Controlled Trials Register, The Cochrane Controlled Trials Register
(CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and
Science Citation Index Expanded. The period of time the separate
searches cover is also given in Table 1. Abstracts of Digestive Dis-
ease Week were searched for meetings from 1996 to 2006. We
also scanned bibliographies in relevant review articles and wrote to
authors of included trials. Two of us (V McAlister, E Davenport)
evaluated whether these studies fulfil the inclusion criteria.
Data collection and analysis
Data extraction
Two reviewers (V. McAlister and E. Davenport) independently
extracted data using standardised extraction forms. Disagreements
were resolved by discussion arbitrated by E. Renuof.
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From each trial, we tried to extract the following characteristics:
• Patients (inclusions and exclusion criteria, mean age, sex,
indication for endoscopic sphincterotomy);
• Interventions (prophylactic cholecystectomy or expectant
management);
• Trials (setting, methodological quality, publication status,
duration of follow-up, and all outcomes).
Methodological quality
Randomisation and follow-up was extracted as measures of
methodological quality using the definitions listed below (
Kjaergard 2001).
Generation of the allocation sequence
To determine if the procedure used to create a random sequence
ensured that each patient has a known, unpredictable, and usually
equal chance of being assigned to intervention groups, the alloca-
tion sequence generation was classified as:
• adequate (if the allocation sequence was generated by a
computer or random number table),
• unclear (if the trial was described as randomised, but the
method used for the allocation sequence generation was not
described), or
• inadequate (if a system involving dates, names, or
admittance numbers were used).
Allocation concealment
The procedure used to conceal the allocation sequence from the
investigators who assign patients to the intervention groups was
assessed. The allocation concealment was classified as:
• adequate (if the allocation of patients involved a central
independent unit, sealed envelopes, on-site locked computer, or
identically appearing numbered drug bottles or containers
prepared by an independent pharmacist),
• unclear (if the trial was described as randomised, but the
method used to conceal the allocation was not described), or
• inadequate (if the trial was quasi-randomised).
Blinding
Considering the nature of the intervention, we did not expect that
any of the eligible trials would be double blind. Double blinding
was, therefore, not be included in our assessment of methodolog-
ical quality. However, we assessed which trials used blinded out-
come assessment.
Follow-up
We extracted the number and reasons for all losses to follow-up to
assess the risk of attrition bias.
Statistical analyses
The analyses was performed in RevMan Analysis 1.0 (RevMan
2003). The number of events and number of patients in all in-
tervention arms was used to calculate relative risks (RR) with
95% confidence intervals (CI). Data were combined in fixed-ef-
fect meta-analyses. Random-effects meta-analyses was performed
as sensitivity analyses, but was only reported if the results regard-
ing significance differed from the fixed-effect models. Intention-
to-treat analyses including all patients irrespective of compliance
or follow-up was performed. Carry forward of the last observed
response was used for patients with missing data. For the primary
outcome measure, evidence of publication bias and other biases
was evaluated in regression analyses of funnel plot asymmetry.
Sources of heterogeneity was evaluated through sensitivity, sub-
group, andmeta-regression analyses. The analyses included the ex-
tracted patient, intervention, and trial characteristics listed above
as explanatory variables. V. McAlister and E. Renouf entered the
data and performed all meta-analyses in RevMan. The impact of
open versus laparoscopic cholecystectomywas assessed by sensitiv-
ity analysis. Sensitivity analysis was also used to assess the impact
of trial design: ERCP alone versus prophylactic cholecystectomy
after ERCP or ERCP alone versus prophylactic cholecystectomy
after common bile duct exploration.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Searches performed on April 18, 2007 resulted in 330 hits which
yielded 93 reports when duplicates were removed. After initial re-
view, seven randomised trials were identified of which two were
excluded on further examination because the gallbladder was not
left in-situ in the patients (Neoptolemos 1987; Kapoor 1996). In
three of the included trials a wait-and-see policy for the gallbladder
after endoscopic sphincterotomy was compared with open chole-
cystectomy and removal of the common bile duct stones by explo-
ration (Hammarstrom 1995; Targarona 1996; Suc 1998). In the
remaining two trials, a wait-and-see approach regarding the gall-
bladder after sphincterotomy was compared with prophylactic la-
paroscopic cholecystectomy after sphincterotomy (Boerma 2002;
Lau 2006). The trials, which were conducted in five countries,
involved multiple centres in two (Suc 1998; Boerma 2002) and
were single-centred in the remaining three (Hammarstrom 1995;
Targarona 1996; Lau 2006). The five trials included 662 adult
patients of whom 334 were allocated to the wait-and-see group
and 328were allocated to the prophylactic cholecystectomy group.
Three trials included patients in all American Society of Anaeste-
siology (ASA) classes (Hammarstrom 1995; Targarona 1996; Suc
1998) and two trials excluded high risk patients with ASA class
IV and V physiological scores (Boerma 2002; Lau 2006).
Risk of bias in included studies
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Allocation concealment was adequate in four trials (Targarona
1996; Suc 1998; Boerma 2002; Lau 2006) but was not described
in one (Hammarstrom 1995). None of the trials was blinded. In
one trial, eight patients were excluded because they did not have
gallbladders-in-situ at the time of randomisation; five in the wait-
and-see group (Suc 1998) and three were in the surgical group. In
two trials, a small number of the patients randomised to the pro-
phylactic cholecystectomy group did not actually have a cholecys-
tectomy (Hammarstrom 1995; Boerma 2002). A follow-up pro-
tocol was described in four trials (Hammarstrom 1995; Targarona
1996; Boerma 2002; Lau 2006). The patients were seen in routine
clinics and third party observers were not used. The trial dura-
tion was disclosed in each trial, but the actual observation period




All five trials, including 662 patients, reported mortality (
Hammarstrom 1995; Targarona 1996; Suc 1998; Boerma 2002;
Lau 2006). Forty seven patients (14.1%) died in the wait-and-see
group and 26 patients (7.9%) died in the prophylactic cholecys-
tectomy group (Analysis 1.1: RR 1.78, 95% CI 1.15 to 2.75, P =
0.010). There was no heterogeneity between the trials (i2 = 0).
Secondary outcomes
All trials reported all of the secondary outcome measures with
the exception of quality-of-life score, which was reported by one
trial only (Boerma 2002). Biliary type pain or cholecystitis oc-
curred in 16% of patients who deferred cholecystectomy and this
riskwas eliminated by prophylactic cholecystectomy (Analysis 1.2:
RR 14.56, 95% CI 4.95 to 42.78, P < 00001). Only four pa-
tients (three in the wait-and-see group and one in the prophylactic
cholecystectomy group) developed pancreatitis (Analysis 1.3: RR
2.11, 95% CI 0.39 to 11.43, P = 0.39). Recurrent jaundice or
cholangitis was significantly more common in patients who de-
ferred cholecystectomy (Analysis 1.4: RR 2.53, 95% CI 1.09 to
5.87, P = 0.03). Less adverse events were recorded in patients who
deferred cholecystectomy (major adverse events: Analysis 1.5: RR
0.59, 95% CI 0.34 to 1.01, P = 0.06 and minor adverse events:
Analysis 1.6: RR 0.49, 95% CI 0.22 to 0.89, P = 0.03). More pa-
tients required subsequent ERCP or other forms of cholangiogra-
phy if cholecystectomy was deferred (Analysis 1.7: RR 2.36, 95%
CI 1.29 to 4.32, P = 0.005). Eight patient randomised to the pro-
phylactic cholecystectomy group did not have a cholecystectomy.
Cholecystectomywas eventually performed in 35% (115 patients)
of the wait-and-see group (Table 1). There was no difference in
the rate of difficult cholecystectomy between the groups (Analysis
1.8: RR 0.68, 95% CI 0.39 to 1.17, P = 0.16). There were no
reports of major orminor bile duct complications following chole-
cystectomy. Only one trial reported hospital re-admission rates (
Targarona 1996) and only one other collected data regarding the
quality of life (Boerma 2002).
Table 1. Actual cholecystectomy rate (prophylactic and therapeutic)
Trial Wait-and-see: n/N Prohylactic: n/N
Hammarstrom 1995 14/39 41/44
Targarona 1996 11/50 48/48
Suc 1998 56/92 102/102
Boerma 2002 22/59 44/49
Lau 2006 12/89 82/82
TOTAL 115/329 317/325
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Subgroup analyses
Subgroup analysis was performed according the design of the tri-
als and according to the inclusion of high-risk patients (Ameri-
can Society of Anaesthesiology (ASA) IV or V). A wait-and-see
policy for the gallbladder after endoscopic sphincterotomy was
compared with open cholecystectomy and removal of the com-
mon bile duct stones by exploration in three trials (Hammarstrom
1995; Targarona 1996; Suc 1998) and a wait-and-see approach
to the gallbladder after endoscopic sphincterotomy was compared
with prophylactic laparoscopic cholecystectomy in the other two
(Boerma 2002; Lau 2006) (Analysis 2.1 to Analysis 2.8). Three
trials included high-risk patients (ASA IV or V) (Hammarstrom
1995; Targarona 1996; Suc 1998) whereas these patients were ex-
cluded in two trials (Boerma 2002; Lau 2006) (Analysis 3.1 to
Analysis 3.8). Therefore, subgroup analysis according to each of
these stratifications were identical. The combination of different
trial design and inclusion of high-risk patients did not alter the
primary or secondary outcomes of the meta-analysis.
Similar reductions in mortality rates were seen in each of the sub-
groups, but combination was required to be statistically significant
(Analysis 2.1; Analysis 3.1). Recurrent biliary pain was seen only
in the patients who deferred cholecystectomy in all subgroups (
Analysis 2.2; Analysis 3.2). Recurrent jaundice and cholangitis oc-
curred more often in the wait-and-see patients in both subgroups
(Analysis 2.4; Analysis 3.4). Additional cholangiography was re-
quired more often in the wait-and-see group in trials comparing it
to prophylactic cholecystectomy after endoscopic sphincterotomy
(Analysis 2.7) and in trials that excluded ASA IV or V patients (
Analysis 3.7), but no difference was present whenwait-and-see was
compared to open cholecystectomy and common bile duct explo-
ration (Analysis 2.7), or in trials that included high-risk patients
(Analysis 3.7). Major adverse events were less common (not sta-
tistically significant) in the wait-and-see patients of all subgroups
(Analysis 2.5; Analysis 3.5). Minor adverse events were reduced
in wait-and-see patients of the trials compared to open cholecys-
tectomy and common bile duct exploration (Analysis 2.6) and
in trials that included ASA IV or V patients (Analysis 3.6) but
not in trials compared to cholecystectomy after sphincterotomy
(Analysis 2.6) nor in trials that excluded high risk patients. The
eventual cholecystectomy rate was 44.8% (81 patients) and 23%
(34 patients) in the wait-and-see group from the open surgery
era and the laparoscopic surgery era respectively (Table 1), but no
difference in the incidence of difficult cholecystectomy was seen
between the eventual and prophylactic cholecystectomies in either
era (Analysis 2.8) nor between trials that included or excluded
high risk patients (Analysis 3.8).
Sensitivity analyses
The influence of each trial on outcome was tested by excluding
each trial in rotation and performing pooled analyses of the re-
maining four trials. The benefit of prophylactic cholecystectomy
remained substantial despite removal of each of the trials, one at
a time, from the analysis. The relative risk of death is given after
the title of each trial which was excluded in the following sensi-
tivity analyses: Boerma 2002 (RR 1.84, 95% CI 1.17 to 2.83);
Hammarstrom 1995 (RR 1.48, 95% CI 0.89 to 2.44); Lau 2006
(RR 1.92, 95% CI 1.09 to 3.4); Suc 1998 (RR 1.72, 95% CI
1.1 to 2.69); Targarona 1996 (RR 2.04, 95% CI 1.22 to 3.41).
The relative risk of biliary pain is given after the title of each trial
which was excluded in the following sensitivity analyses: Boerma
2002 (RR 9.49, 95%CI 2.96 to 30.38); Hammarstrom 1995 (RR
12.83, 95%CI 3.96 to 41.60); Lau 2006 (RR 17.92, 95%CI 5.11
to 64.07); Suc 1998 (RR 15.26, 95% 4.79 to 48.68); Targarona
1996 (RR 18.49, 95% CI 5.19 to 65.86). The relative risk of
jaundice or cholangitis is given after the title of each trial which
was excluded in the following sensitivity analyses: Boerma 2002
(RR 2.54, 1.06 to 6.07); Hammarstrom 1995 (RR 2.53, 95% CI
1.09 to 5.87); Lau 2006 (RR 2.89, 95% CI 0.58 to 14.37); Suc
1998 (RR 2.76, 95% CI 1.13 to 6.72); Targarona 1996 (RR 2.22,
95% CI 0.91 to 5.37). Exclusion of any one trial did not qualita-
tively alter RR but the 95% CI for some of the analyses crossed
unity if the following studies were excluded: Hammarstrom 1995
(RR mortality 1.48, 95% CI 0.89 to 2.44); Lau 2006 (RR re-
current jaundice or cholangitis 2.89, 95% CI 0.58 to 14.37) and
Targarona 1996 (RR recurrent jaundice or cholangitis 2.22, 95%
CI 0.91 to 5.37).
D I S C U S S I O N
The main conclusions of our review are that the wait-and-see pro-
cedure versus removal of the gallbladder leads to more deaths,
more patients with biliary pain and cholangitis, more patients with
recurrent jaundice and cholangitis, and more additional cholan-
giographies, but saves cholecystectomies and adverse events. The
major limitations of our review are the relatively few trials, the few
patients, and the low number of outcomes as well as methodolog-
ical weaknesses of the trials.
One of the included trials demonstrated a statistically significant
increase in mortality in patients deferring cholecystectomy af-
ter endoscopic sphincterotomy and clearance of the bile duct (
Hammarstrom 1995). This trial had a small sample size and its
finding might be considered a matter of chance. Subsequent stud-
ies were not sufficiently powered to show differences in survival
and therefore could not confirm the finding. A surprisingly large
proportion of patients have been reported to adopt a wait-and-see
policy after sphincterotomy, indicating that neither physicians nor
patients have been convinced by the trials individually (Archibald
2007). This meta-analysis confirms the finding that prophylactic
cholecystectomy after endoscopic sphincterotomy reducesmortal-
ity. This reduction in mortality was seen particularly in trials that
included all patients, even those in the higher risk ASA classes.
This finding was evident even though most of the high-risk pa-
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tients were in trials that compared a wait-and-see policy to open
surgery. Cholecystectomy deferral has been advised for high risk
patients, but this meta-analysis suggests that the benefit of pro-
phylactic cholecystectomy may accrue particularly to that group
of patients.
Technological developments have defined eras in the management
of cholelithiasis. The development of ERCP in the late 1980s and
of laparoscopy in the 1990s changed the management of gallblad-
der and common bile duct stones. Randomised clinical trials of
a wait-and-see policy were designed to use as a control the tech-
nology of their era for bile duct clearance and cholecystectomy.
Subgroup analysis showed the superiority of prophylactic chole-
cystectomy to occur regardless of study design. Superiority of pro-
phylactic cholecystectomy was present even in patients who had
open surgery. The laparoscopic approach reduces the morbidity
of cholecystectomy and has extended use of the procedure into
groups of patients previously thought too frail for open surgery (
Barkun 2005). It is reasonable to consider prophylactic cholecys-
tectomy for patients in all risk categories after endoscopic sphinc-
terotomy. However, no trial of prophylactic cholecystectomy has
yet been carried out in patients initially considered high-risk for
surgery.
Laparoscopic common bile duct exploration may alter the options
available to deal with choledocholithiasis once again (Cuschieri
2002). Avoiding the risk of pancreatitis that is inherent with en-
doscopic sphincterotomy is an attractive element of common bile
duct exploration. Of the patients who underwent common bile
duct clearance followed by prophylactic cholecystectomy in this
review, 7.1% died in the earlier era where choledocholithiasis was
dealt with by open common bile duct exploration, whereas 9.2%
died in the later endoscopic / laparoscopic era. More trials will
be required as new technological solutions, such as robot-assisted
common bile duct exploration with its capacity for articulated dis-
section, are deployed. This meta-analysis demonstrates the impor-
tance of designing such trials with appropriate power.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Prophylactic cholecystectomy should be offered to all patients
considered fit for surgery, in whom choledocholithiasis has been
cleared by ERCP and endoscopic sphincterotomy.
Implications for research
Prophylactic cholecystectomy following clearance of choledo-
cholithiasis should be studied by randomised clinical trial in pa-
tients considered high-risk for surgery.
Future trials should be reported following the recommendations
of the CONSORT statement (www.consort-statement.org).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boerma 2002
Methods Generation of the allocation sequence: adequate. Computer randomisation with stratification according
to participating hospital and whether older or younger than 65 years.
Allocation concealment: adequate. Central allocation.
Blinding: not performed.
Follow-up: 5/64 in the wait-and-see group and 7/56 in the prophylactic cholecystectomy group were
immediately lost to follow-up.
Analysis: intention to treat excluding those immediately lost to follow-up.
Participants Country and setting: Netherlands, one Academic Heath Centre and eight Community Hospitals.
Language: English.
Inclusion criteria: consecutive male and female patients, aged 18 to 80 having ERCP/ES with successful
extraction of CBD stones and radiographically-proven choledocholithiasis.
Exclusion criteria: ASA IV or V, deemed unfit for surgery.
Allocation: ES with wait-and-see = 49; prophylactic cholecystectomy = 59.
Interventions Wait-and-see group: ES with “on-demand” cholecystectomy.
Prophylactic cholecystectomy group: laparoscopic cholecystectomy within 6 weeks of ES.
Outcomes Primary outcome: recurrence of at least 1 biliary event during 2 year follow-up (biliary pain, acute
cholecystitis, cholangitis, pancreatitis, obstructive jaundice, gallstone ileus, GB carcinoma).
Secondary outcome: complications of cholecystectomy, quality-of-life (measured using MOS-24).
Complications: post-procedure complications.
Notes Follow-up: median follow up: 30 months.
’Other’ outcomes and/or adverse events of interest: mortality, additional ERCP, conversion to open chole-
cystectomy.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Hammarstrom 1995
Methods Generation of the allocation sequence: adequate. Random number allocation.
Allocation concealment: unclear.
Blinding: not performed.
Follow-up: three of 44 patients in the prophylactic cholecystectomy group and none of 39 in the wait-
and-see group were lost to follow-up.
Analysis: intention to treat.
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Hammarstrom 1995 (Continued)
Participants Country and setting: Sweden, academic health centre.
Language: English.
Inclusion criteria: male and female patients, aged 55 to 85 with demonstration of CBD stones (by ERCP
in 79 patients, ultrasonography in 2 patients, or infusion cholangiography in 2 patients).
Exclusion criteria: previous cholecystectomy, unfit for surgery, concomitant malignancy, Billroth II gas-
trectomy, refused participation, perforated cholecystitis, referred from local hospital.
Allocation: wait-and-see = 39, prophylactic cholecystectomy n = 44.
Interventions Wait-and-see group: ERCP and ES with eventual cholecystectomy if required. (Authors do not state if
the laparoscopic or open approach is to be taken).
Prophylactic cholecystectomy group: open cholecystectomywith supraduodenal bile duct exploration and
T-tube placement in all patients; 25 of 41 patients had choledochoscopy.
Outcomes Authors do not explicitly state which of their outcomes were considered to be primary and which are
secondary.
Outcome was assessed in terms of mortality, major (life-threatening)and minor (non-life threatening)
complications, length of hospital stay, and late morbidity.
Notes Follow-up: for wait-and see group median follow-up was 92 months and for cholecystectomy group
median follow-up was 82 months.
Total median hospital stay of 13 days was reported only for the ES group (no hospital length of stay data
for the surgical group).
Other outcomes of interest: repeat ERCP.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Lau 2006
Methods Generation of the allocation sequence: adequate. Randomly assigned using computer-generated random
list.
Allocation concealment: adequate. Performed by research nurse from computer.
Blinding: not performed.
Follow-up: no patients lost to follow-up.
Participants Country and setting: Hong Kong, Academic Health Centre.
Language: English.
Inclusion criteria: consecutive patients who underwent complete sphincterotomy and complete removal of
CBD stones eligible if radiologic evidence of intact GB containing stones and no previous hospitalisation
for cholecystitis.
Exclusion criteria: age > 90, evidence of concomitant intrahepatic ductal stones, radiologic evidence of
recurrent pyogenic cholangitis, no consent to trial entry, intercurrent malignancy with limited life span,
unfit for cholecystectomy (ASA class IV or V).
Allocation: wait-and-see = 88, prophylactic cholecystectomy n = 82.
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Lau 2006 (Continued)
Interventions Wait-and-see group: ES with possible eventual cholecystectomy.
Prophylactic cholecystectomy group: laparoscopic cholecystectomy after ES.
Outcomes Primary outcome: further biliary complications presenting with cholangitis, pancreatitis, jaundice, com-
plicated gallstones presenting with biliary colic (as defined by the Rome II criteria), or cholecystitis .
Secondary outcome: adverse events, late deaths from all causes, outcomes after cholecystectomy.
Notes Follow-up: mean follow-up in the prophylactic cholecystectomy group was 65.5 months, compared with
58.5 months in the wait-and-see group.
’Other’ outcomes and/or adverse events of interest included mortality, additional ERCP, conversion to
open surgery, median hospital stay during index admission.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Suc 1998
Methods Generation of the allocation sequence: adequate. Random number table and central coordinating center.
Allocation concealment: adequate. Central allocation.
Blinding: not performed.
Follow-up: not described.
Participants Country and setting: France, nine university hospitals, eight teaching hospitals and one private hospital.
Language: English.
Inclusion criteria: consecutive patients with one or more of: clinical symptoms including jaundice, mild
acute pancreatitis with Ranson score less than or equal to 2, mild acute cholangitis, biliary colic with
increased alkaline phophatase levels, CBD stones, or CBD diameter > 1 cm on ultrasonography.
Exclusion criteria: cholecystitis (GB wall > 3 mm on US), no cholelithiasis visible on US, CBD diameter
< 1 cm, previous total gastrectomy, B2, or choledochoenterostomy.
Allocation: wait-and-see - 95 (5 already had GB removed at time of randomisation); prophylactic chole-
cystectomy group - 105 (3 already GB removed at time of randomisation).
Interventions Wait-and-see group: ERCP followed by cholecystectomy if required later.
Prophylactic cholecystectomy group: open cholecystectomy and open CBD exploration.
Outcomes Primary outcome: number of patients requiring an additional procedure.
Secondary outcomes: mortality, major complications, duration of hospital stay.
Notes
Risk of bias
Item Authors’ judgement Description
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Suc 1998 (Continued)
Allocation concealment? Yes A - Adequate
Targarona 1996
Methods Generation of the allocation sequence: adequate. Patients randomly assigned to one of two arms and
stratified according to presence of jaundice or pancreatitis.
Allocation concealment: adequate. Sequentially numbered, sealed envelopes.
Blinding: not performed.
Follow-up: adequate. Follow-up: 3/48 of prophylactic cholecystectomy group and 1/50 of wait-and-see
group lost to follow-up.
Analysis: intention to treat.
Participants Country and setting: Spain, on academic health centre.
Language: English.
Inclusion criteria: all male and female ’high-risk’ gallstone patients (at least one of: age over 70; Goldman
cardiac risk index >13; chronic pulmonary disease with a predicted postoperative maximum sustained
ventilation <10 L/min; liver cirrhosis type B or C of the Child-Pugh classification; neurologic deficit
or joint disease associated with severely impaired mobility; BMI >30) presenting with biliary pain and
jaundice, pancreatitis, cholangitis, or any combination thereof, and suspected of having common bile
duct stones were candidates for inclusion.
Diagnostic criteria used for bile duct stones: cholestasis associated with evidence of GB stones and CBD
> 8 mm and/or duct stones by abdominal US or ERCP. If ERCP required for diagnosis then patient
randomised during the procedure.
Exclusion criteria: patient refusal, previous surgical or endoscopic interventions on the biliary tree, pre-
senting with severe cholangitis or biliary pancreatitis requiring urgent ES.
Allocation: ES with GB in situ = 50; cholecystectomy = 48.
Interventions Wait-and-see group: ES with cholecystectomy later if required.
Prophylactic cholecystectomy group: open cholecystectomy with CBD exploration if indicated by intra-
operative cholangiography.
Outcomes Authors do not explicitly state which of their outcomes are primary and which are secondary.
Outcomes assessed:
(1) immediate, procedure-related: mortality and morbidity, severe complications, minor complications,
pre-procedure and post-procedure hospital length of stay.
(2) during long-term follow-up: biliary complications, readmission for biliary complications, cholecystec-
tomy, ERCP, late morbidity.
Notes Early follow-up defined as follow-up to hospital discharge. Late follow-up protocol included a visit at 30
days or so after discharge and then every three months for first year and every six months thereafter for
the length of the study.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Abbreviations
ASA: American Society of Anesthesiology physiological status score
CBD: Common bile duct
GB: Gallbladder
ERCP: Endoscopic Retrograde Cholangiopancreatography
ES: Endoscopic sphincterotomy
Characteristics of excluded studies [ordered by study ID]
Kapoor 1996 A randomised clinical trial. Neither treatment arm included patients left with gallbladder in situ.
Neoptolemos 1987 A randomised clinical trial. Neither treatment arm included patients left with gallbladder in situ.
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D A T A A N D A N A L Y S E S
Comparison 1. Wait-and-see versus prophylactic cholecystectomy




participants Statistical method Effect size
1 Mortality 5 662 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [1.15, 2.75]
2 Biliary pain or cholecystitis 5 654 Risk Ratio (M-H, Fixed, 95% CI) 14.56 [4.95, 42.78]
3 Pancreatitis 5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [0.39, 11.43]
4 Recurrent jaundice or cholangitis 5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.09, 5.87]
5 Major adverse events 5 662 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.35, 1.02]
6 Minor adverse events 5 662 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.22, 0.91]
7 Additional cholangiography
(ERCP or PTC)
5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [1.29, 4.32]
8 Difficult cholecystectomy 5 654 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.39, 1.17]
Comparison 2. Stratified by method of cholecystectomy




participants Statistical method Effect size
1 Mortality 5 662 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.10, 2.64]
1.1 Open cholecystectomy &
common bile duct exploration




2 279 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.79, 2.94]
2 Biliary pain or cholecystitis 5 654 Risk Ratio (M-H, Fixed, 95% CI) 14.56 [4.95, 42.78]
2.1 Open cholecystectomy &
common bile duct exploration




2 279 Risk Ratio (M-H, Fixed, 95% CI) 18.84 [3.66, 97.00]
3 Pancreatitis 5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [0.39, 11.43]
3.1 Open cholecystectomy &
common bile duct exploration




2 279 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Recurrent jaundice or cholangitis 5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.09, 5.87]
4.1 Open cholecystectomy &
common bile duct exploration




2 279 Risk Ratio (M-H, Fixed, 95% CI) 2.41 [0.94, 6.18]
5 Major adverse events 5 662 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.35, 1.02]
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5.1 Open cholecystectomy &
common bile duct exploration




2 279 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.21, 1.04]
6 Minor adverse events 5 662 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.22, 0.91]
6.1 Open cholecystectomy &
common bile duct exploration




2 279 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.32, 3.27]
7 Additional cholangiography
(ERCP or PTC)
5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [1.29, 4.32]
7.1 Open cholecystectomy &
common bile duct exploration




2 279 Risk Ratio (M-H, Fixed, 95% CI) 20.40 [2.82, 147.51]
8 Difficult cholecystectomy 5 654 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.39, 1.17]
8.1 Open cholecystectomy &
common bile duct exploration




2 279 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.36, 1.10]
Comparison 3. Stratified by patient ASA class




participants Statistical method Effect size
1 Mortality 5 662 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.10, 2.64]
1.1 Studies with inclusion of
high-risk patients (ASA IV or
V)
3 383 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [1.03, 3.35]
1.2 Studies with exclusion of
high-risk patients (ASA IV or
V)
2 279 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.79, 2.94]
2 Biliary pain or cholecystitis 5 654 Risk Ratio (M-H, Fixed, 95% CI) 14.56 [4.95, 42.78]
2.1 Studies with inclusion of
high-risk patients (ASA IV or
V)
3 375 Risk Ratio (M-H, Fixed, 95% CI) 11.09 [2.69, 45.79]
2.2 Studies with exclusion of
high-risk patients (ASA IV or
V)
2 279 Risk Ratio (M-H, Fixed, 95% CI) 18.84 [3.66, 97.00]
3 Pancreatitis 5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [0.39, 11.43]
3.1 Studies with inclusion of
high-risk patients (ASA IV or
V)
3 383 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [0.39, 11.43]
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3.2 Studies with exclusion of
high-risk patients (ASA IV or
V)
2 279 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Recurrent jaundice or cholangitis 5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.09, 5.87]
4.1 Studies with inclusion of
high-risk patients (ASA IV or
V)
3 383 Risk Ratio (M-H, Fixed, 95% CI) 3.04 [0.47, 19.49]
4.2 Studies with exclusion of
high-risk patients (ASA IV or
V)
2 279 Risk Ratio (M-H, Fixed, 95% CI) 2.41 [0.94, 6.18]
5 Major adverse events 5 662 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.35, 1.02]
5.1 Studies with inclusion of
high-risk patients (ASA IV or
V)
3 383 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.35, 1.53]
5.2 Studies with exclusion of
high-risk patients (ASA IV or
V)
2 279 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.21, 1.04]
6 Minor adverse events 5 662 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.22, 0.91]
6.1 Studies with inclusion of
high-risk patients (ASA IV or
V)
3 383 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.11, 0.73]
6.2 Studies with exclusion of
high-risk patients (ASA IV or
V)
2 279 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.32, 3.27]
7 Additional cholangiography
(ERCP or PTC)
5 662 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [1.29, 4.32]
7.1 Studies with inclusion of
high-risk patients (ASA IV or
V)
3 383 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.45, 1.94]
7.2 Studies with exclusion of
high-risk patients (ASA IV or
V)
2 279 Risk Ratio (M-H, Fixed, 95% CI) 20.40 [2.82, 147.51]
8 Difficult cholecystectomy 5 654 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.39, 1.17]
8.1 Studies with inclusion of
high-risk patients (ASA IV or
V)
3 375 Risk Ratio (M-H, Fixed, 95% CI) 3.38 [0.14, 80.52]
8.2 Studies with exclusion of
high-risk patients (ASA IV or
V)
2 279 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.36, 1.10]
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Analysis 1.1. Comparison 1 Wait-and-see versus prophylactic cholecystectomy, Outcome 1 Mortality.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 1 Wait-and-see versus prophylactic cholecystectomy
Outcome: 1 Mortality
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boerma 2002 1/59 1/49 4.1 % 0.83 [ 0.05, 12.94 ]
Hammarstrom 1995 14/39 5/44 17.8 % 3.16 [ 1.25, 7.97 ]
Lau 2006 19/89 11/82 43.4 % 1.59 [ 0.81, 3.14 ]
Suc 1998 3/97 1/105 3.6 % 3.25 [ 0.34, 30.70 ]
Targarona 1996 10/50 8/48 31.0 % 1.20 [ 0.52, 2.78 ]
Total (95% CI) 334 328 100.0 % 1.78 [ 1.15, 2.75 ]
Total events: 47 (Wait-and-see), 26 (Prophylactic removal)
Heterogeneity: Chi2 = 2.99, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
0.01 0.1 1 10 100
Favours wait-and-see Favours removal
Analysis 1.2. Comparison 1 Wait-and-see versus prophylactic cholecystectomy, Outcome 2 Biliary pain or
cholecystitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 1 Wait-and-see versus prophylactic cholecystectomy
Outcome: 2 Biliary pain or cholecystitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boerma 2002 25/59 0/49 15.4 % 42.50 [ 2.65, 680.67 ]
Hammarstrom 1995 11/39 0/44 13.2 % 25.88 [ 1.57, 425.17 ]
Lau 2006 7/89 1/82 29.3 % 6.45 [ 0.81, 51.30 ]
Suc 1998 4/92 0/102 13.4 % 9.97 [ 0.54, 182.66 ]
Targarona 1996 5/50 1/48 28.7 % 4.80 [ 0.58, 39.60 ]
Total (95% CI) 329 325 100.0 % 14.56 [ 4.95, 42.78 ]
Total events: 52 (Wait-and-see), 2 (Prophylactic removal)
Heterogeneity: Chi2 = 2.45, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.87 (P < 0.00001)
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Analysis 1.3. Comparison 1 Wait-and-see versus prophylactic cholecystectomy, Outcome 3 Pancreatitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 1 Wait-and-see versus prophylactic cholecystectomy
Outcome: 3 Pancreatitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boerma 2002 0/59 0/49 0.0 [ 0.0, 0.0 ]
Hammarstrom 1995 1/39 0/44 3.38 [ 0.14, 80.52 ]
Lau 2006 0/89 0/82 0.0 [ 0.0, 0.0 ]
Suc 1998 1/97 1/105 1.08 [ 0.07, 17.07 ]
Targarona 1996 1/50 0/48 2.88 [ 0.12, 69.07 ]
Total (95% CI) 334 328 2.11 [ 0.39, 11.43 ]
Total events: 3 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
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Analysis 1.4. Comparison 1 Wait-and-see versus prophylactic cholecystectomy, Outcome 4 Recurrent
jaundice or cholangitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 1 Wait-and-see versus prophylactic cholecystectomy
Outcome: 4 Recurrent jaundice or cholangitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boerma 2002 1/59 0/49 2.50 [ 0.10, 60.03 ]
Hammarstrom 1995 0/39 0/44 0.0 [ 0.0, 0.0 ]
Lau 2006 13/89 5/82 2.40 [ 0.89, 6.43 ]
Suc 1998 1/97 1/105 1.08 [ 0.07, 17.07 ]
Targarona 1996 3/50 0/48 6.73 [ 0.36, 126.85 ]
Total (95% CI) 334 328 2.53 [ 1.09, 5.87 ]
Total events: 18 (Wait-and-see), 6 (Prophylactic removal)
Heterogeneity: Chi2 = 0.80, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
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Analysis 1.5. Comparison 1 Wait-and-see versus prophylactic cholecystectomy, Outcome 5 Major adverse
events.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 1 Wait-and-see versus prophylactic cholecystectomy
Outcome: 5 Major adverse events
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boerma 2002 8/59 8/49 27.3 % 0.83 [ 0.34, 2.05 ]
Hammarstrom 1995 3/39 6/44 17.6 % 0.56 [ 0.15, 2.11 ]
Lau 2006 0/89 7/82 24.4 % 0.06 [ 0.00, 1.06 ]
Suc 1998 5/97 6/105 18.0 % 0.90 [ 0.28, 2.86 ]
Targarona 1996 3/50 4/48 12.7 % 0.72 [ 0.17, 3.05 ]
Total (95% CI) 334 328 100.0 % 0.60 [ 0.35, 1.02 ]
Total events: 19 (Wait-and-see), 31 (Prophylactic removal)
Heterogeneity: Chi2 = 3.54, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
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Analysis 1.6. Comparison 1 Wait-and-see versus prophylactic cholecystectomy, Outcome 6 Minor adverse
events.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 1 Wait-and-see versus prophylactic cholecystectomy
Outcome: 6 Minor adverse events
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boerma 2002 5/59 3/49 13.7 % 1.38 [ 0.35, 5.50 ]
Hammarstrom 1995 4/39 6/44 23.6 % 0.75 [ 0.23, 2.47 ]
Lau 2006 1/89 2/82 8.7 % 0.46 [ 0.04, 4.99 ]
Suc 1998 0/97 5/105 22.1 % 0.10 [ 0.01, 1.76 ]
Targarona 1996 0/50 7/48 32.0 % 0.06 [ 0.00, 1.09 ]
Total (95% CI) 334 328 100.0 % 0.45 [ 0.22, 0.91 ]
Total events: 10 (Wait-and-see), 23 (Prophylactic removal)
Heterogeneity: Chi2 = 6.16, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 2.24 (P = 0.025)
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Analysis 1.7. Comparison 1 Wait-and-see versus prophylactic cholecystectomy, Outcome 7 Additional
cholangiography (ERCP or PTC).
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 1 Wait-and-see versus prophylactic cholecystectomy
Outcome: 7 Additional cholangiography (ERCP or PTC)
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boerma 2002 6/59 0/49 3.8 % 10.83 [ 0.63, 187.63 ]
Hammarstrom 1995 5/39 6/44 38.9 % 0.94 [ 0.31, 2.84 ]
Lau 2006 16/89 0/82 3.6 % 30.43 [ 1.86, 499.28 ]
Suc 1998 6/97 6/105 39.7 % 1.08 [ 0.36, 3.24 ]
Targarona 1996 1/50 2/48 14.1 % 0.48 [ 0.04, 5.12 ]
Total (95% CI) 334 328 100.0 % 2.36 [ 1.29, 4.32 ]
Total events: 34 (Wait-and-see), 14 (Prophylactic removal)
Heterogeneity: Chi2 = 10.65, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 2.79 (P = 0.0053)
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Analysis 1.8. Comparison 1 Wait-and-see versus prophylactic cholecystectomy, Outcome 8 Difficult
cholecystectomy.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 1 Wait-and-see versus prophylactic cholecystectomy
Outcome: 8 Difficult cholecystectomy
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boerma 2002 12/59 9/49 1.11 [ 0.51, 2.41 ]
Hammarstrom 1995 1/39 0/44 3.38 [ 0.14, 80.52 ]
Lau 2006 6/89 16/82 0.35 [ 0.14, 0.84 ]
Suc 1998 0/92 0/102 0.0 [ 0.0, 0.0 ]
Targarona 1996 0/50 0/48 0.0 [ 0.0, 0.0 ]
Total (95% CI) 329 325 0.68 [ 0.39, 1.17 ]
Total events: 19 (Wait-and-see), 25 (Prophylactic removal)
Heterogeneity: Chi2 = 4.73, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 2.1. Comparison 2 Stratified by method of cholecystectomy, Outcome 1 Mortality.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 2 Stratified by method of cholecystectomy
Outcome: 1 Mortality
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Open cholecystectomy % common bile duct exploration
Hammarstrom 1995 14/39 5/44 17.8 % 3.16 [ 1.25, 7.97 ]
Suc 1998 1/97 1/105 3.6 % 1.08 [ 0.07, 17.07 ]
Targarona 1996 10/50 8/48 31.0 % 1.20 [ 0.52, 2.78 ]
Subtotal (95% CI) 186 197 52.4 % 1.86 [ 1.03, 3.35 ]
Total events: 25 (Wait-and-see), 14 (Prophylactic removal)
Heterogeneity: Chi2 = 2.45, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 2.05 (P = 0.040)
2 Laparoscopic cholecystectomy after sphincterotomy
Boerma 2002 1/59 1/49 4.1 % 0.83 [ 0.05, 12.94 ]
Lau 2006 19/89 11/82 43.4 % 1.59 [ 0.81, 3.14 ]
Subtotal (95% CI) 148 131 47.6 % 1.53 [ 0.79, 2.94 ]
Total events: 20 (Wait-and-see), 12 (Prophylactic removal)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 334 328 100.0 % 1.70 [ 1.10, 2.64 ]
Total events: 45 (Wait-and-see), 26 (Prophylactic removal)
Heterogeneity: Chi2 = 2.78, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
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Analysis 2.2. Comparison 2 Stratified by method of cholecystectomy, Outcome 2 Biliary pain or
cholecystitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 2 Stratified by method of cholecystectomy
Outcome: 2 Biliary pain or cholecystitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Open cholecystectomy % common bile duct exploration
Hammarstrom 1995 11/39 0/44 13.2 % 25.88 [ 1.57, 425.17 ]
Suc 1998 4/92 0/102 13.4 % 9.97 [ 0.54, 182.66 ]
Targarona 1996 5/50 1/48 28.7 % 4.80 [ 0.58, 39.60 ]
Subtotal (95% CI) 181 194 55.3 % 11.09 [ 2.69, 45.79 ]
Total events: 20 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00088)
2 Laparoscopic cholecystectomy after spincterotomy
Boerma 2002 25/59 0/49 15.4 % 42.50 [ 2.65, 680.67 ]
Lau 2006 7/89 1/82 29.3 % 6.45 [ 0.81, 51.30 ]
Subtotal (95% CI) 148 131 44.7 % 18.84 [ 3.66, 97.00 ]
Total events: 32 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 1.36, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 3.51 (P = 0.00044)
Total (95% CI) 329 325 100.0 % 14.56 [ 4.95, 42.78 ]
Total events: 52 (Wait-and-see), 2 (Prophylactic removal)
Heterogeneity: Chi2 = 2.45, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.87 (P < 0.00001)
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Analysis 2.3. Comparison 2 Stratified by method of cholecystectomy, Outcome 3 Pancreatitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 2 Stratified by method of cholecystectomy
Outcome: 3 Pancreatitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Open cholecystectomy % common bile duct exploration
Hammarstrom 1995 1/39 0/44 3.38 [ 0.14, 80.52 ]
Suc 1998 1/97 1/105 1.08 [ 0.07, 17.07 ]
Targarona 1996 1/50 0/48 2.88 [ 0.12, 69.07 ]
Subtotal (95% CI) 186 197 2.11 [ 0.39, 11.43 ]
Total events: 3 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
2 Laparoscopic cholecystectomy after sphincterotomy
Boerma 2002 0/59 0/49 0.0 [ 0.0, 0.0 ]
Lau 2006 0/89 0/82 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 148 131 0.0 [ 0.0, 0.0 ]
Total events: 0 (Wait-and-see), 0 (Prophylactic removal)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 334 328 2.11 [ 0.39, 11.43 ]
Total events: 3 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
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Analysis 2.4. Comparison 2 Stratified by method of cholecystectomy, Outcome 4 Recurrent jaundice or
cholangitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 2 Stratified by method of cholecystectomy
Outcome: 4 Recurrent jaundice or cholangitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Open cholecystectomy % common bile duct exploration
Hammarstrom 1995 0/39 0/44 0.0 [ 0.0, 0.0 ]
Suc 1998 1/97 1/105 1.08 [ 0.07, 17.07 ]
Targarona 1996 3/50 0/48 6.73 [ 0.36, 126.85 ]
Subtotal (95% CI) 186 197 3.04 [ 0.47, 19.49 ]
Total events: 4 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
2 Laparoscopic cholecystectomy after sphincterotomy
Boerma 2002 1/59 0/49 2.50 [ 0.10, 60.03 ]
Lau 2006 13/89 5/82 2.40 [ 0.89, 6.43 ]
Subtotal (95% CI) 148 131 2.41 [ 0.94, 6.18 ]
Total events: 14 (Wait-and-see), 5 (Prophylactic removal)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.068)
Total (95% CI) 334 328 2.53 [ 1.09, 5.87 ]
Total events: 18 (Wait-and-see), 6 (Prophylactic removal)
Heterogeneity: Chi2 = 0.80, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
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Analysis 2.5. Comparison 2 Stratified by method of cholecystectomy, Outcome 5 Major adverse events.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 2 Stratified by method of cholecystectomy
Outcome: 5 Major adverse events
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Open cholecystectomy % common bile duct exploration
Hammarstrom 1995 3/39 6/44 17.6 % 0.56 [ 0.15, 2.11 ]
Suc 1998 5/97 6/105 18.0 % 0.90 [ 0.28, 2.86 ]
Targarona 1996 3/50 4/48 12.7 % 0.72 [ 0.17, 3.05 ]
Subtotal (95% CI) 186 197 48.3 % 0.73 [ 0.35, 1.53 ]
Total events: 11 (Wait-and-see), 16 (Prophylactic removal)
Heterogeneity: Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Laparoscopic cholecystectomy after sphincterotomy
Boerma 2002 8/59 8/49 27.3 % 0.83 [ 0.34, 2.05 ]
Lau 2006 0/89 7/82 24.4 % 0.06 [ 0.00, 1.06 ]
Subtotal (95% CI) 148 131 51.7 % 0.47 [ 0.21, 1.04 ]
Total events: 8 (Wait-and-see), 15 (Prophylactic removal)
Heterogeneity: Chi2 = 3.50, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.86 (P = 0.063)
Total (95% CI) 334 328 100.0 % 0.60 [ 0.35, 1.02 ]
Total events: 19 (Wait-and-see), 31 (Prophylactic removal)
Heterogeneity: Chi2 = 3.54, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
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Analysis 2.6. Comparison 2 Stratified by method of cholecystectomy, Outcome 6 Minor adverse events.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 2 Stratified by method of cholecystectomy
Outcome: 6 Minor adverse events
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Open cholecystectomy % common bile duct exploration
Hammarstrom 1995 4/39 6/44 23.6 % 0.75 [ 0.23, 2.47 ]
Suc 1998 0/97 5/105 22.1 % 0.10 [ 0.01, 1.76 ]
Targarona 1996 0/50 7/48 32.0 % 0.06 [ 0.00, 1.09 ]
Subtotal (95% CI) 186 197 77.6 % 0.28 [ 0.11, 0.73 ]
Total events: 4 (Wait-and-see), 18 (Prophylactic removal)
Heterogeneity: Chi2 = 4.17, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 2.62 (P = 0.0087)
2 Laparoscopic cholecystectomy after sphincterotomy
Boerma 2002 5/59 3/49 13.7 % 1.38 [ 0.35, 5.50 ]
Lau 2006 1/89 2/82 8.7 % 0.46 [ 0.04, 4.99 ]
Subtotal (95% CI) 148 131 22.4 % 1.03 [ 0.32, 3.27 ]
Total events: 6 (Wait-and-see), 5 (Prophylactic removal)
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 334 328 100.0 % 0.45 [ 0.22, 0.91 ]
Total events: 10 (Wait-and-see), 23 (Prophylactic removal)
Heterogeneity: Chi2 = 6.16, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 2.24 (P = 0.025)
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Analysis 2.7. Comparison 2 Stratified by method of cholecystectomy, Outcome 7 Additional
cholangiography (ERCP or PTC).
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 2 Stratified by method of cholecystectomy
Outcome: 7 Additional cholangiography (ERCP or PTC)
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Open cholecystectomy % common bile duct exploration
Hammarstrom 1995 5/39 6/44 38.9 % 0.94 [ 0.31, 2.84 ]
Suc 1998 6/97 6/105 39.7 % 1.08 [ 0.36, 3.24 ]
Targarona 1996 1/50 2/48 14.1 % 0.48 [ 0.04, 5.12 ]
Subtotal (95% CI) 186 197 92.7 % 0.93 [ 0.45, 1.94 ]
Total events: 12 (Wait-and-see), 14 (Prophylactic removal)
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Laparoscopic cholecystectomy after sphincterotomy
Boerma 2002 6/59 0/49 3.8 % 10.83 [ 0.63, 187.63 ]
Lau 2006 16/89 0/82 3.6 % 30.43 [ 1.86, 499.28 ]
Subtotal (95% CI) 148 131 7.3 % 20.40 [ 2.82, 147.51 ]
Total events: 22 (Wait-and-see), 0 (Prophylactic removal)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
Total (95% CI) 334 328 100.0 % 2.36 [ 1.29, 4.32 ]
Total events: 34 (Wait-and-see), 14 (Prophylactic removal)
Heterogeneity: Chi2 = 10.65, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 2.79 (P = 0.0053)
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Analysis 2.8. Comparison 2 Stratified by method of cholecystectomy, Outcome 8 Difficult cholecystectomy.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 2 Stratified by method of cholecystectomy
Outcome: 8 Difficult cholecystectomy
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Open cholecystectomy % common bile duct exploration
Hammarstrom 1995 1/39 0/44 3.38 [ 0.14, 80.52 ]
Suc 1998 0/92 0/102 0.0 [ 0.0, 0.0 ]
Targarona 1996 0/50 0/48 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 181 194 3.38 [ 0.14, 80.52 ]
Total events: 1 (Wait-and-see), 0 (Prophylactic removal)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Laparoscopic cholecystectomy after sphincterotomy
Boerma 2002 12/59 9/49 1.11 [ 0.51, 2.41 ]
Lau 2006 6/89 16/82 0.35 [ 0.14, 0.84 ]
Subtotal (95% CI) 148 131 0.63 [ 0.36, 1.10 ]
Total events: 18 (Wait-and-see), 25 (Prophylactic removal)
Heterogeneity: Chi2 = 3.78, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 1.61 (P = 0.11)
Total (95% CI) 329 325 0.68 [ 0.39, 1.17 ]
Total events: 19 (Wait-and-see), 25 (Prophylactic removal)
Heterogeneity: Chi2 = 4.73, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 3.1. Comparison 3 Stratified by patient ASA class, Outcome 1 Mortality.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 3 Stratified by patient ASA class
Outcome: 1 Mortality
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with inclusion of high-risk patients (ASA IV or V)
Hammarstrom 1995 14/39 5/44 17.8 % 3.16 [ 1.25, 7.97 ]
Suc 1998 1/97 1/105 3.6 % 1.08 [ 0.07, 17.07 ]
Targarona 1996 10/50 8/48 31.0 % 1.20 [ 0.52, 2.78 ]
Subtotal (95% CI) 186 197 52.4 % 1.86 [ 1.03, 3.35 ]
Total events: 25 (Wait-and-see), 14 (Prophylactic removal)
Heterogeneity: Chi2 = 2.45, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 2.05 (P = 0.040)
2 Studies with exclusion of high-risk patients (ASA IV or V)
Boerma 2002 1/59 1/49 4.1 % 0.83 [ 0.05, 12.94 ]
Lau 2006 19/89 11/82 43.4 % 1.59 [ 0.81, 3.14 ]
Subtotal (95% CI) 148 131 47.6 % 1.53 [ 0.79, 2.94 ]
Total events: 20 (Wait-and-see), 12 (Prophylactic removal)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 334 328 100.0 % 1.70 [ 1.10, 2.64 ]
Total events: 45 (Wait-and-see), 26 (Prophylactic removal)
Heterogeneity: Chi2 = 2.78, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
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Analysis 3.2. Comparison 3 Stratified by patient ASA class, Outcome 2 Biliary pain or cholecystitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 3 Stratified by patient ASA class
Outcome: 2 Biliary pain or cholecystitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with inclusion of high-risk patients (ASA IV or V)
Hammarstrom 1995 11/39 0/44 13.2 % 25.88 [ 1.57, 425.17 ]
Suc 1998 4/92 0/102 13.4 % 9.97 [ 0.54, 182.66 ]
Targarona 1996 5/50 1/48 28.7 % 4.80 [ 0.58, 39.60 ]
Subtotal (95% CI) 181 194 55.3 % 11.09 [ 2.69, 45.79 ]
Total events: 20 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00088)
2 Studies with exclusion of high-risk patients (ASA IV or V)
Boerma 2002 25/59 0/49 15.4 % 42.50 [ 2.65, 680.67 ]
Lau 2006 7/89 1/82 29.3 % 6.45 [ 0.81, 51.30 ]
Subtotal (95% CI) 148 131 44.7 % 18.84 [ 3.66, 97.00 ]
Total events: 32 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 1.36, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 3.51 (P = 0.00044)
Total (95% CI) 329 325 100.0 % 14.56 [ 4.95, 42.78 ]
Total events: 52 (Wait-and-see), 2 (Prophylactic removal)
Heterogeneity: Chi2 = 2.45, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.87 (P < 0.00001)
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Analysis 3.3. Comparison 3 Stratified by patient ASA class, Outcome 3 Pancreatitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 3 Stratified by patient ASA class
Outcome: 3 Pancreatitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with inclusion of high-risk patients (ASA IV or V)
Hammarstrom 1995 1/39 0/44 3.38 [ 0.14, 80.52 ]
Suc 1998 1/97 1/105 1.08 [ 0.07, 17.07 ]
Targarona 1996 1/50 0/48 2.88 [ 0.12, 69.07 ]
Subtotal (95% CI) 186 197 2.11 [ 0.39, 11.43 ]
Total events: 3 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
2 Studies with exclusion of high-risk patients (ASA IV or V)
Boerma 2002 0/59 0/49 0.0 [ 0.0, 0.0 ]
Lau 2006 0/89 0/82 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 148 131 0.0 [ 0.0, 0.0 ]
Total events: 0 (Wait-and-see), 0 (Prophylactic removal)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 334 328 2.11 [ 0.39, 11.43 ]
Total events: 3 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
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Analysis 3.4. Comparison 3 Stratified by patient ASA class, Outcome 4 Recurrent jaundice or cholangitis.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 3 Stratified by patient ASA class
Outcome: 4 Recurrent jaundice or cholangitis
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with inclusion of high-risk patients (ASA IV or V)
Hammarstrom 1995 0/39 0/44 0.0 [ 0.0, 0.0 ]
Suc 1998 1/97 1/105 1.08 [ 0.07, 17.07 ]
Targarona 1996 3/50 0/48 6.73 [ 0.36, 126.85 ]
Subtotal (95% CI) 186 197 3.04 [ 0.47, 19.49 ]
Total events: 4 (Wait-and-see), 1 (Prophylactic removal)
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
2 Studies with exclusion of high-risk patients (ASA IV or V)
Boerma 2002 1/59 0/49 2.50 [ 0.10, 60.03 ]
Lau 2006 13/89 5/82 2.40 [ 0.89, 6.43 ]
Subtotal (95% CI) 148 131 2.41 [ 0.94, 6.18 ]
Total events: 14 (Wait-and-see), 5 (Prophylactic removal)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.068)
Total (95% CI) 334 328 2.53 [ 1.09, 5.87 ]
Total events: 18 (Wait-and-see), 6 (Prophylactic removal)
Heterogeneity: Chi2 = 0.80, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
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Analysis 3.5. Comparison 3 Stratified by patient ASA class, Outcome 5 Major adverse events.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 3 Stratified by patient ASA class
Outcome: 5 Major adverse events
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with inclusion of high-risk patients (ASA IV or V)
Hammarstrom 1995 3/39 6/44 17.6 % 0.56 [ 0.15, 2.11 ]
Suc 1998 5/97 6/105 18.0 % 0.90 [ 0.28, 2.86 ]
Targarona 1996 3/50 4/48 12.7 % 0.72 [ 0.17, 3.05 ]
Subtotal (95% CI) 186 197 48.3 % 0.73 [ 0.35, 1.53 ]
Total events: 11 (Wait-and-see), 16 (Prophylactic removal)
Heterogeneity: Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Studies with exclusion of high-risk patients (ASA IV or V)
Boerma 2002 8/59 8/49 27.3 % 0.83 [ 0.34, 2.05 ]
Lau 2006 0/89 7/82 24.4 % 0.06 [ 0.00, 1.06 ]
Subtotal (95% CI) 148 131 51.7 % 0.47 [ 0.21, 1.04 ]
Total events: 8 (Wait-and-see), 15 (Prophylactic removal)
Heterogeneity: Chi2 = 3.50, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.86 (P = 0.063)
Total (95% CI) 334 328 100.0 % 0.60 [ 0.35, 1.02 ]
Total events: 19 (Wait-and-see), 31 (Prophylactic removal)
Heterogeneity: Chi2 = 3.54, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
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Analysis 3.6. Comparison 3 Stratified by patient ASA class, Outcome 6 Minor adverse events.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 3 Stratified by patient ASA class
Outcome: 6 Minor adverse events
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with inclusion of high-risk patients (ASA IV or V)
Hammarstrom 1995 4/39 6/44 23.6 % 0.75 [ 0.23, 2.47 ]
Suc 1998 0/97 5/105 22.1 % 0.10 [ 0.01, 1.76 ]
Targarona 1996 0/50 7/48 32.0 % 0.06 [ 0.00, 1.09 ]
Subtotal (95% CI) 186 197 77.6 % 0.28 [ 0.11, 0.73 ]
Total events: 4 (Wait-and-see), 18 (Prophylactic removal)
Heterogeneity: Chi2 = 4.17, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 2.62 (P = 0.0087)
2 Studies with exclusion of high-risk patients (ASA IV or V)
Boerma 2002 5/59 3/49 13.7 % 1.38 [ 0.35, 5.50 ]
Lau 2006 1/89 2/82 8.7 % 0.46 [ 0.04, 4.99 ]
Subtotal (95% CI) 148 131 22.4 % 1.03 [ 0.32, 3.27 ]
Total events: 6 (Wait-and-see), 5 (Prophylactic removal)
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 334 328 100.0 % 0.45 [ 0.22, 0.91 ]
Total events: 10 (Wait-and-see), 23 (Prophylactic removal)
Heterogeneity: Chi2 = 6.16, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 2.24 (P = 0.025)
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Analysis 3.7. Comparison 3 Stratified by patient ASA class, Outcome 7 Additional cholangiography (ERCP
or PTC).
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 3 Stratified by patient ASA class
Outcome: 7 Additional cholangiography (ERCP or PTC)
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with inclusion of high-risk patients (ASA IV or V)
Hammarstrom 1995 5/39 6/44 38.9 % 0.94 [ 0.31, 2.84 ]
Suc 1998 6/97 6/105 39.7 % 1.08 [ 0.36, 3.24 ]
Targarona 1996 1/50 2/48 14.1 % 0.48 [ 0.04, 5.12 ]
Subtotal (95% CI) 186 197 92.7 % 0.93 [ 0.45, 1.94 ]
Total events: 12 (Wait-and-see), 14 (Prophylactic removal)
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Studies with exclusion of high-risk patients (ASA IV or V)
Boerma 2002 6/59 0/49 3.8 % 10.83 [ 0.63, 187.63 ]
Lau 2006 16/89 0/82 3.6 % 30.43 [ 1.86, 499.28 ]
Subtotal (95% CI) 148 131 7.3 % 20.40 [ 2.82, 147.51 ]
Total events: 22 (Wait-and-see), 0 (Prophylactic removal)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
Total (95% CI) 334 328 100.0 % 2.36 [ 1.29, 4.32 ]
Total events: 34 (Wait-and-see), 14 (Prophylactic removal)
Heterogeneity: Chi2 = 10.65, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 2.79 (P = 0.0053)
0.001 0.01 0.1 1 10 100 1000
Favours wait-and-see Favours removal
38Cholecystectomy deferral in patients with endoscopic sphincterotomy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.8. Comparison 3 Stratified by patient ASA class, Outcome 8 Difficult cholecystectomy.
Review: Cholecystectomy deferral in patients with endoscopic sphincterotomy
Comparison: 3 Stratified by patient ASA class
Outcome: 8 Difficult cholecystectomy
Study or subgroup Wait-and-see Prophylactic removal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with inclusion of high-risk patients (ASA IV or V)
Hammarstrom 1995 1/39 0/44 3.38 [ 0.14, 80.52 ]
Suc 1998 0/92 0/102 0.0 [ 0.0, 0.0 ]
Targarona 1996 0/50 0/48 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 181 194 3.38 [ 0.14, 80.52 ]
Total events: 1 (Wait-and-see), 0 (Prophylactic removal)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Studies with exclusion of high-risk patients (ASA IV or V)
Boerma 2002 12/59 9/49 1.11 [ 0.51, 2.41 ]
Lau 2006 6/89 16/82 0.35 [ 0.14, 0.84 ]
Subtotal (95% CI) 148 131 0.63 [ 0.36, 1.10 ]
Total events: 18 (Wait-and-see), 25 (Prophylactic removal)
Heterogeneity: Chi2 = 3.78, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 1.61 (P = 0.11)
Total (95% CI) 329 325 0.68 [ 0.39, 1.17 ]
Total events: 19 (Wait-and-see), 25 (Prophylactic removal)
Heterogeneity: Chi2 = 4.73, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 1.40 (P = 0.16)
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A P P E N D I C E S
Appendix 1. Search Strategies
Database Timespan of search Search strategy
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
April 2007. cholecystectom* AND sphincterotom* and choledocholithiasis
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(Continued)
Cochrane Central Register of Controlled
Trials in The Cochrane Library
Issue 1 2007. #1MeSH descriptor Cholecystectomy explode all trees inMeSH
products
#2 cholecystectom* in All Fields in all products
#3 (#1 OR #2)
#4 MeSH descriptor Sphincterotomy, Endoscopic explode all
trees in MeSH products
#5 sphincterotom* in All Fields in all products
#6 (#4 OR #5)
#7 MeSH descriptor Choledocholithiasis explode all trees in
MeSH products
#8 Choledocholithiasis in All Fields in all products
#9 (#7 OR #8)
#10 (#3 AND #6 AND #9)
MEDLINE (WinSPIRS 5.0) 1950 to April 2007. #1 explode “Cholecystectomy”/all subheadings
#2 cholecystectom*
#3 #1 or #2
#4 explode “Sphincterotomy-Endoscopic”/all subheadings
#5 sphincterotom*
#6 #4 or #5
#7 explode “Choledocholithiasis”/all subheadings
#8 choledocholithiasis
#9 #7 or #8
#10 #3 and #6 and #9
#11 random* or blind* or placebo* or meta-analysis
#12 #10 and #11
EMBASE (WinSPIRS 5.0) 1980 to April 2007. #1 explode “cholecystectomy”/all subheadings
#2 cholecystectom*
#3 #1 or #2
#4 explode “sphincterotomy”/all subheadings
#5 sphincterotom*
#6 #4 or #5
#7 explode “common-bile-duct-stone”/all subheadings
#8 choledocholithiasis
#9 #7 or #8
#10 #3 and #6 and #9
#11 random* or blind* or placebo* or meta-analysis
#12 #10 and #11
Science Citation Index Expanded (http://
portal.isiknowledge.com/portal.cgi?
DestApp=WOS&Func=Frame)
1945 to April 2007. #1 12,359 TS=cholecystectom*
#2 3,852 TS=sphincterotom*
#3 1,788 TS=choledocholithiasis
#4 409 #3 AND #2 AND #1
#5 >100,000 TS=(random* or blind* or placebo* or meta-anal-
ysis)
#6 60 #5 AND #4
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Last assessed as up-to-date: 27 July 2007.
24 September 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 4, 2007
C O N T R I B U T I O N S O F A U T H O R S
V McAlister is responsible for correspondence. Search strategies were designed and run by Sarah Louse Klinkenberg, The Cochrane
Hepato-Biliary Group Trials Search Co-ordinator, and they were approved by all authors. E Davenport searched the abstracts of
Digestive Disease Week. V McAlister and E Renouf independently reviewed the search results for potential studies to be included. E
Davenport and E Renouf assessed the trials and extracted data. Differences were resolved by V McAlister after discussion. V McAlister
performed the analyses on RevMan 4.2. E Davenport and E Renouf reviewed the analyses. V McAlister wrote the first draft of the
report . Revisions were suggested by E Davenport and E Renouf. All authors approved of the final review before submission.
D E C L A R A T I O N S O F I N T E R E S T
V McAlister is a surgeon who performs endoscopic retrograde cholangio-pancreatography, common bile duct exploration, and chole-
cystectomy.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Cholecystectomy; ∗Sphincterotomy, Endoscopic; Choledocholithiasis [mortality; ∗surgery]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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